Iloprost液4℃保存的胎鼠皮层组织移植修复脑损伤的实验研究

为探讨脑组织移植治疗脑损伤及供体组织的保存，作者在制造大鼠运动区皮层损伤的基础上，分别以新鲜及Ｉｌｏｐｒｏｓｔ液或生理盐水保存３小时的胎鼠歧层组织为供体，将其移植到损的大鼠中，观察移植后的神经行为变化及形态学改变。     

人自然杀伤细胞抑制性受体P58.2基因克隆与鉴定

目的：P58．2基因克隆与鉴定。方法：采用RT—PCR技术，从正常人外周血单个核细胞中扩增自然杀伤细胞抑制性受体P58．2基因全长cDNA，经酶切后构建重组克隆载体，双酶切和测序鉴定。结果：RT—PCR获得了预期的扩增产物P58．2全长cDNA，成功构建了pSPORT1-P58．2重组克隆载体，酶切、酶谱分析与预期结果相符。DNA测序结果与GenBank登记的人P58．2cDNA全长碱基序列一致。结论：pSPORT1-P58．2重组克隆载体构建成功；P58．2基因序列与文献报道一致，为下一步构建表达载体和基因转染等工作打下良好的基础。     

Unusual presentation of common acute lymphoblastic leukemia antigen-positive extramedullary disease in childhood. Two patients with isolated masseter muscle involvement.

Two children with unusual extramedullary common acute lymphoblastic leukemia antigen (CALLA)-positive (CD10) disease are reported. Isolated masseter infiltration with CD10/CD19-positive lymphoblasts was present in both patients with no other evidence of disease. One child had relapse of common acute lymphoblastic leukemia, and the other had primary disease. Disease may have spread from lymph nodes overlying the masseter muscle. Immunophenotyping and immunogenotyping provided a rapid and accurate diagnosis for both children.     

Clinico pathologic analysis of 1503 thyroid tumors]

A clinicopathologic analysis of 1503 thyroid tumors was conducted revealing 82.9% of benign and 17.8% of malignant lesions. The most common type of benign tumor was simple adenoma (62.1%) and of malignant tumor, papillary adenocarcinoma (52.5%). The malignant to benign tumor ratio was 1:4.8. The male to female sex ratio was 1:2.6 in the malignant and 1:3.8 in the benign tumors. The overall 5- and 10-year survival rates for all cancers were 67.7% and 47.6%, respectively. It is suggested that the follicular carcinoma could further be divided into well differentiated (papillary and follicular), poorly differentiated (including squamous cell carcinoma) and undifferentiated types.     

Autologe Verfahren zur Therapie von Gefäßinfektionen

The development of a deep infection following vascular reconstructive surgery is the most demanding situation encountered in vascular surgery and requires diagnostic investigations that will vary with the hospital concerned and a targeted, early and aggressive attack on the infection both systemically and locally; in addition, local reconstruction carried out with autologous materials in association with sutures that are absorbed over the medium term – also referred to as autologous reconstruction – is helpful in many cases. A range of autologous reconstruction procedures is available for application at all sites of infection, allowing adequate and effective treatment. In most cases these can ensure a secure blood flow situation, win time, and keep the patient alive and conserve his or her extremity. The main priority is to combat the infection and make it possible to keep the patient alive and the extremity affected intact. When the stage of deep infection has been reached even recovery of the initial status once the infection is cured can be regarded as a success. After an appropriate time it is always possible to reoperate on the basis of the principles of vascular surgery.     

Prof. Shan Zhaowei＇s Experience in Treating Atrophic Gastritis

Prof. Shan Zhaowei （ 单兆伟 ）, the author＇s teacher, has been engaged in TCM for more than 30 years, with profound knowledge in the treatment of diseases of the spleen and stomach, which are introduced in the following.     

Treatment options for primary splenic low‐grade non‐Hodgkin's lymphomas

The purpose of this comparative study was to evaluate the response of primary splenic low‐grade non‐Hodgkin's lymphomas (NHL) to chemotherapy, splenectomy, and chemotherapy combined with splenectomy in order to elaborate the optimum treatment modality. A total of 104 patients (age range: 15–82 years) with primary low‐grade B‐cell NHL of the spleen were comprised by our study. Stage IV disease was determined in 102 (98.1%) cases. Regarding the treatment modality, splenectomy was performed in 14 patients, early splenectomy and single‐agent chemotherapy in 15, early splenectomy and combined chemotherapy in 19, single‐agent chemotherapy in 23, and combined chemotherapy in 33. In the above‐mentioned order, complete remission rate was following: none, 40.0, 31.6, 21.8, and 18.2%. Partial remissions were achieved in 85.7, 46.7, 57.9, 30.4, and 69.7% of cases, respectively. The median remission duration turned out to be longer (74.5 months) in the group of patients with complete remissions attained by means of splenectomy and combined chemotherapy. Local relapses in the spleen developed in 19 (72.7%) patients treated with combined chemotherapy and in 9 (90.0%), who had undergone single‐agent chemotherapy. The 5‐year overall survival was 54.4% after splenectomy, 39.4% after single‐agent chemotherapy, and 37.1% after combined chemotherapy, being significantly higher (P < 0.05) after splenectomy and single‐agent chemotherapy (67.2%), and splenectomy followed by combined chemotherapy (64.7%). Early splenectomy combined with chemotherapy is the optimum treatment option for primary low‐grade NHL of the spleen because of the superiority in complete remission rate, remission duration, and in overall survival rate. Splenectomy leads to somatic compensation of patients, makes impossible local relapsing in the spleen, prevents continuous dissemination from the primary tumor site, and mostly corrects cytopenias, creating better conditions for chemotherapy.     

The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with Parkinson's disease.

We conducted a case-control study to determine the prevalence of the LRRK2 Gly2385Arg variant in patients with Parkinson's disease in Han population in mainland China. Heterozygous LRRK2 Gly2385Arg variant was identified in 14 of 235 patients with Parkinson's disease (5.69%), but not in 214 unrelated healthy controls. Multivariate analysis indicated the frequency of Gly2385Arg variant in the female patients with early age at onset is higher than their male counterparts. The founder haplotype analysis showed the variant carriers shared the same founder. Clinically, the LRRK2 Gly2385Arg carriers presented with classical Parkinson's disease symptoms. Our study indicates that the LRRK2 Gly2385Arg variant is a potential ethnic-specific genetic risk factor of Parkinson's disease within Chinese Han ethnicity.     

A fluid level in an acute extradural haematoma

We report a fluid level in an acute extradural haematoma developing after placement of a ventriculoperitoneal shunt for hydrocephalus. This fluid level was thought to be due to a mixture of blood and cerebrospinal fluid.     

Carboxylic acid replacement structure-activity relationships in suosan type sweeteners. A sweet taste antagonist. 1.

N-(4-Cyanophenyl)-N'-(2-carboxyethyl)urea (2), an analogue of suosan [1,N-(4-nitrophenyl)-N'-(2-carboxyethyl)urea], is a known high-potency sweetener derived from beta-alanine. Sulfonic and phosphonic acid analogues of 2 were prepared to develop structure-activity relationships through modification of the carboxylic acid region of this family of sweeteners. Neither of the carboxylic acid replacements resulted in sweet analogues. However, we found that N-(4-cyanophenyl)-N'-[(sodiosulfo)methyl]urea (7) is an antagonist of the sweet taste response. The bitter taste response to caffeine, quinine, and naringin was also antagonized. Antagonist 7 was found to inhibit the sweet taste perception of a variety of sweeteners. Antagonist 7 had no effect on the sour or salty taste response.